poisar

Stocks · News reference

Coya Therapeutics Announces Publication Of Preclinical Results For COYA 303 In International Journal Of Molecular Sciences; Results Show Complementary Immunomodulatory Effects In Peripheral And CNS Inflammation

Benzinga Newsdesk

Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or GLP-1RA as

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

COYA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    $32 Million Exosome Therapy Market Assessment 2026: Set to Experience Massive Growth, Reaching $1.4 Billion by 2040

    The global exosome therapy market is projected to grow from $32 million in 2026 to $1.4 billion by 2040, with a CAGR of 41.1%. Key growth drivers include expanding clinical pipelines, increased regulatory filings, and rising investment in regenerative medicine. Ophthalmology and oncology represent major therapeutic areas, while Asia-Pacific is positioned as a leading market. However, challenges include inconsistent therapeutic preparations, contamination risks, and quality control complexities.

    COYA